View in EDS

Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation.

Saved in:
Bibliographic Details
Title: Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation.
Authors: Smith JM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barlaam B; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Bradshaw L; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Chan HM; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Cooke SL; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cronin A; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cumming I; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Dean E; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Debreczeni JÉ; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barco Barrantes ID; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ferguson D; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Gianni D; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Grondine M; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Lynch JT; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., McWilliams L; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Moore S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Raubo P; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Qu Y; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China., Robb GR; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Tan L; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China., Urosevic J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Vazquez-Chantada M; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Wang P; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China.
Source: Journal of medicinal chemistry [J Med Chem] 2026 Jun 11; Vol. 69 (11), pp. 13725-13752. Date of Electronic Publication: 2026 May 22.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42172174
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Smith+JM%22">Smith JM</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Barlaam+B%22">Barlaam B</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Beattie+D%22">Beattie D</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Bradshaw+L%22">Bradshaw L</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Chan+HM%22">Chan HM</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Cooke+SL%22">Cooke SL</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Cronin+A%22">Cronin A</searchLink>; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Cumming+I%22">Cumming I</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Dean+E%22">Dean E</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Debreczeni+JÉ%22">Debreczeni JÉ</searchLink>; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Barco+Barrantes+ID%22">Barco Barrantes ID</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Ferguson+D%22">Ferguson D</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Gianni+D%22">Gianni D</searchLink>; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Grondine+M%22">Grondine M</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Lynch+JT%22">Lynch JT</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22McWilliams+L%22">McWilliams L</searchLink>; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Moore+S%22">Moore S</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Raubo+P%22">Raubo P</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Qu+Y%22">Qu Y</searchLink>; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China.<br /><searchLink fieldCode="AU" term="%22Robb+GR%22">Robb GR</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Tan+L%22">Tan L</searchLink>; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China.<br /><searchLink fieldCode="AU" term="%22Urosevic+J%22">Urosevic J</searchLink>; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Vazquez-Chantada+M%22">Vazquez-Chantada M</searchLink>; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Wang+P%22">Wang P</searchLink>; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229716531%22">Journal of medicinal chemistry</searchLink> [J Med Chem] 2026 Jun 11; Vol. 69 (11), pp. 13725-13752. <i>Date of Electronic Publication: </i>2026 May 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Chemical+Society%22">American Chemical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9716531 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1520-4804 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200222623%22">00222623 </searchLink><i>NLM ISO Abbreviation: </i>J Med Chem <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42172174
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1021/acs.jmedchem.6c00659
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 13725
    Titles:
      – TitleFull: Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Smith JM
      – PersonEntity:
          Name:
            NameFull: Barlaam B
      – PersonEntity:
          Name:
            NameFull: Beattie D
      – PersonEntity:
          Name:
            NameFull: Bradshaw L
      – PersonEntity:
          Name:
            NameFull: Chan HM
      – PersonEntity:
          Name:
            NameFull: Cooke SL
      – PersonEntity:
          Name:
            NameFull: Cronin A
      – PersonEntity:
          Name:
            NameFull: Cumming I
      – PersonEntity:
          Name:
            NameFull: Dean E
      – PersonEntity:
          Name:
            NameFull: Debreczeni JÉ
      – PersonEntity:
          Name:
            NameFull: Barco Barrantes ID
      – PersonEntity:
          Name:
            NameFull: Ferguson D
      – PersonEntity:
          Name:
            NameFull: Gianni D
      – PersonEntity:
          Name:
            NameFull: Grondine M
      – PersonEntity:
          Name:
            NameFull: Lynch JT
      – PersonEntity:
          Name:
            NameFull: McWilliams L
      – PersonEntity:
          Name:
            NameFull: Moore S
      – PersonEntity:
          Name:
            NameFull: Raubo P
      – PersonEntity:
          Name:
            NameFull: Qu Y
      – PersonEntity:
          Name:
            NameFull: Robb GR
      – PersonEntity:
          Name:
            NameFull: Tan L
      – PersonEntity:
          Name:
            NameFull: Urosevic J
      – PersonEntity:
          Name:
            NameFull: Vazquez-Chantada M
      – PersonEntity:
          Name:
            NameFull: Wang P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 06
              Text: 2026 Jun 11
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1520-4804
          Numbering:
            – Type: volume
              Value: 69
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Journal of medicinal chemistry
              Type: main
ResultId 1